In addition, tumor-infiltrating CD8+ T cells of the mice treated with anti-PD-L1 and/or anti-CCL5 antibodies exhibited enhanced IFN-γ production relative to the control isotype mice, especially in the combination treatment group (Fig. 6e). The gene discussed is CD8A; the disease is neoplasm.